Sequence Bio
90% of drug candidates fail, delaying help for those in need. We’re on a mission to change that. Better drug target discovery powered by the Newfoundland founder effect.
Y Combinator
yc-company-directory #144690% of drug candidates fail, delaying help for those in need. We’re on a mission to change that. Better drug target discovery powered by the Newfoundland founder effect.
sourceSequence Bio is classified as Healthcare from source descriptions and fund-directory context. Similar companies below are ranked from offline product facets and meaningful description overlap; category and source affiliation can only strengthen an existing product match. For lookup-created rows, the profile starts as pending enrichment until deeper source collection runs.
Local clusters rerank extracted product concepts and description terms. The generated graph remains the fallback for sparse descriptions: offline reciprocal product-similarity graph: extracted concepts + description terms + bounded category/affiliation boosts. Minimum fallback score: 0; max competitors: 6.
Companies similar to Sequence Bio
A deterministic local cluster built from offline product facets and meaningful description terms. Category and selected-institution affiliation provide bounded tie-breaks. Open any peer to continue exploring its cluster.
Harmonic Discovery
match 48We are a drug discovery company developing a new generation of therapeutics that embrace the complexity of disease. Currently available approaches for creating drugs work on the principle of finding one drug-one protein 'magic bullets'. However, diseases such as cancer and autoimmunity are often the result of several dysregulated proteins across many distinct biological pathways. We are building a computational-experimental platform to design therapeutics that can target several disease-causing
shared extracted concept terms: drug, discovery; shared product terms: drug, discovery, target; same category: Healthcare; shared affiliation: Y Combinator
Fairwaves
match 44We're reinventing mobile networks for those who need them the most
shared extracted concept terms: those, need; shared product terms: re, those, need
Valink Therapeutics
match 43Valink Therapeutics develops next generation antibody-based therapeutics. We identify novel mechanism of action from known targets by incorporating multiple antibody modifications at once, rapidly and scalable generating complex drug candidates (bi-/multispecificity, multivalency and drug-conjugation in a single discovery process). Our research focus is on solid tumours poorly addressed by immunotherapy.
shared extracted concept terms: target; shared product terms: drug, candidate, target, discovery; shared affiliation: Y Combinator
NeuroX1
match 36Computational drug discovery leveraging generative AI to create therapeutics for neurodegenerative disorders.
shared extracted concept terms: drug, discovery; shared product terms: drug, discovery
Liricare
match 36Creating the world’s largest network of special needs professionals, connecting them with those who need them the most
shared extracted concept terms: those, need; shared product terms: need, those
Kernal Biologics
match 35Kernal Bio is a biotech company pioneering mRNA 2.0 immunotherapies. We leverage selective mRNA-LNP technology to treat cancer and autoimmune diseases with precision, ensuring targeted cell delivery and minimal off-target effects. Our KR-402 program achieves over 90% delivery efficiency with T-cell-targeted LNPs, enabling direct CAR-T programming within the body and resulting in B-cell depletion within a week. Kernal Bio is led by a team with experience from MIT, Harvard, Merck, and BMS, boastin
shared extracted concept terms: target; shared product terms: target, effect, 90; shared affiliation: Y Combinator